Skip to main content
Signal8

LivaNova PLC (LIVN)

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Sector: Electromedical & Electrotherapeutic Apparatus

Industry: Medical - Devices

LivaNova PLC logo

LivaNova PLC

NASDAQ:LIVNHealthcare
-0.46%$80.90
AH Close$80.90+0.00%vs close
Mkt Cap$4.46B
Float54.9M
O/S55.09M
Inst Own-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$4.46B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 55.09M shares outstanding

SectorHealthcare
IndustryMedical - Devices
ExchangeNASDAQ
CountryGBGB
IPO DateOct 19, 2015
Shares Outstanding55.09M
Float54.90M
Company Overview

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions.

The company operates through three key segments.

Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers.

The company's products are distributed globally through both its direct sales force and independent distributors.

Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Leadership

Vladimir Makatsaria

Chief Executive Officer & Director

Alex Shvartsburg

Chief Financial Officer

Natalia Sergeyevna Kozmina

Chief Human Resources Officer

Ahmet Tezel

Chief Innovation Officer

Employees

3K+

Country

GB

Sector

Healthcare

Website

livanova.com

Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$91.50+13.1%
Low $85High $105
Ratings Distribution
BUY
11
HOLD
3
SELL
1
TOTAL15
Insider Trading
InsiderTypeShares
Liddy Anne M. profile photoLiddy Anne M.Grant/Award6.3K
Bianchi Francesco profile photoBianchi FrancescoSale3.5K
Story Brooke profile photoStory BrookeSale2.3K
Bianchi Francesco profile photoBianchi FrancescoSale1.6K
Tezel Ahmet profile photoTezel AhmetOption Exercise12.7K
Tezel Ahmet profile photoTezel AhmetWithholding/Transfer8.6K
Shareholders
-
Institutionalⓘ
(304)
0.4%
Insiderⓘ
(17)
0.0%
5%+ Owners
(0)
-
Unattributed (incl. retail)ⓘ
Insider0.4%
Top Shareholders
Sources: 13F, Form 4, 13D/13GO/S: 55.1M · as of 29 Jul 2026 · SEC cover page
Insiders & Institutional Holders
52-Week Range
$41.02$79.38
$80.90(100th percentile)
Volume
Average Daily Volume603.86K
572.06K today vs 603.86K avg(-5%)

30d Avg

603.86K

60d Avg

624.65K

90d Avg

653.92K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...